Oramed Pharmaceuticals Inc.
2 Elza Street
210 articles with Oramed Pharmaceuticals Inc.
Annual Clinical Trials Summit is taking place on April 29-30, 2019 in Barcelona, Spain.
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been allowed by the United States Patent and Trademark Office.
H.C. Wainwright Global Life Sciences Conference is taking place April 8-9, 2019 in London.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and using Same" has been allowed by the United States Patent and Trademark Office.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application (
The BIO CEO & Investor Conference is taking place February 11-12, 2019 in New York City.
This is the first study of ORMD-0901 under Oramed's existing FDA Investigational New Drug application
We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTIT received to date to $33 million.
Totaling $33 M in payments from HTIT received to date
The double-blind, randomized study for type 2 diabetes was initiated in April 2018 and is designed to generate meaningful data for both efficacy (HbA1c) and safety endpoints.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking place on November 6-9, 2018 in Amsterdam.
Oramed Pharmaceuticals Inc. announced today that a scientific abstract summarizing two recent Phase IIb studies of its orally ingestible insulin capsule, ORMD-0801 in type 1 and type 2 diabetes patients will be presented in a poster at the 13th annual Cardiometabolic Health Congress in Boston, MA.
The three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH.
Oramed Pharmaceuticals Inc.announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection
Oramed Pharmaceuticals Inc. announced that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide."
Oramed Pharmaceuticals Inc. announced the closing of its previously-announced registered direct offering with several healthcare-focused institutional investors.
Oramed Pharmaceuticals Inc. announced today that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in a registered direct offering of 2,892,000 shares of its common stock
Study will provide additional metabolic data on ORMD-0801 in patients with type 1 diabetes
Up to 48 subjects will be enrolled including 24 healthy volunteers and 24 subjects with type 1 diabetes.